Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

• Tarik Asselah ,

  * E-mail: tarik.asselah@aphp.fr

  Affiliation Hepatology Department, Beaujon Hospital, University of Paris, Paris, France

  ⨯
• Christophe Moreno,

  Affiliation CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Christoph Sarrazin,

  Affiliation Johann Wolfgang Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany

  ⨯
• Michael Gschwantler,

  Affiliation Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria

  ⨯
• Graham R. Foster,

  Affiliation Queen Mary Hospital, University of London, Barts Health, London, United Kingdom

  ⨯
• Antonio Craxí,

  Affiliation Sezione di Gastroenterologia & Epatologia, Di.Bi.M.I.S., University of Palermo, Palermo, Italy

  ⨯
• Peter Buggisch,

  Affiliation Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany

  ⨯
• Faisal Sanai,

  Affiliation Division of Gastroenterology, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia

  ⨯
• Ceyhun Bicer,

  Affiliation Janssen Infectious Diseases BVBA, Beerse, Belgium

  ⨯
• Oliver Lenz,

  Affiliation Janssen Infectious Diseases BVBA, Beerse, Belgium

  ⨯
• Gino Van Dooren,

  Affiliation Janssen Infectious Diseases BVBA, Beerse, Belgium

  ⨯
• Catherine Nalpas,

  Affiliation Janssen Pharmaceuticals, Paris, France

  ⨯
• Isabelle Lonjon-Domanec,

  Affiliation Janssen Pharmaceuticals, Paris, France

  ⨯
• Michael Schlag,

  Affiliation Janssen-Cilag, Vienna, Austria

  ⨯
• Maria Buti

  Affiliation Liver Unit, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain

  ⨯